REACT, a patent-pending technology available only in SHOEBOX Audiometry ensures test accuracy by continuously monitoring for conditions such as patient response behavior and environmental conditions. The dynamic reactions replace the manual adjustments the audiologist would make during testing.
Tablet technology is revolutionizing almost every industry. That's why we chose the iPad as the platform for our audiometer. And although the tablet format makes it unique, our software is what makes it disruptive. The beauty of software is that it keeps getting better and allows us to continue to innovate. But the audiometer is only one component of our full solution.
Here we are, already 3 months into 2018 and I'm only now sitting down to write the article. It's been a hectic start to the year. But the bulk of events that we attend happen in the spring and again in the fall. So now seems a good time to capture the audiology conferences in 2018 that we are both committed to, and considering.
Audiometers are very precise electronic instruments used for testing human hearing. They are regulated by ANSI/ASA S3.6-2010, which is the standard that provides the specifications and tolerances for such devices. To ensure that your audiometer continues to function accurately and conform to the standard, it is necessary for you to routinely check and verify the audiometer. Called a biological calibration or verification, these checks are performed to confirm that the system is free of any defects that might erroneously impact test results.
Tuberculosis (TB) is a global pandemic, and multi-drug resistant tuberculosis (MDR-TB) presents additional, unique challenges for those who suffer from this debilitating disease. Existing drug treatments are multifactorial and complex with lengthy treatment regimens, complicated administration, and toxic secondary effects. The costly treatment of drug- resistant TB can take up to two years and presents significant challenges to health systems, payers, and patients. Recognizing that significant hearing loss can be a side effect of the current treatment regimen for MDR-TB, there is a need to closely monitor patients undergoing treatment with existing and new drug therapies.